Final Stage II Results of the CLL11 Trial: Obinutuzumab/Chlorambucil (Clb) versus Rituximab/Clb for Patients with CLL and Coexisting Conditions


Final Stage II Results of the CLL11 Trial: Obinutuzumab/Chlorambucil (Clb) versus Rituximab/Clb for Patients with CLL and Coexisting Conditions
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Brad S Kahl, MD (2/13/14)
Goede V et al. Head-to-head comparison of obinutuzumab (GA101) plus chlorambucil (Clb) versus rituximab plus Clb in patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities): Final Stage 2 results of the CLL11 trial. Proc ASH 2013;Abstract 6.

Goede V et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;[Epub ahead of print]. Abstract

Dr Kahl is Skoronski Chair of Lymphoma Research and Associate Professor at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical Research at the UW Carbone Cancer Center in Madison, Wisconsin.